DAPTOMICINA DR REDDY'S

Informazioni principali

  • Nome commerciale:
  • DAPTOMICINA DR REDDY'S
  • Utilizzare per:
  • Esseri umani
  • Tipo di medicina:
  • Farmaco allopatico

Documenti

  • per il pubblico:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per il pubblico.

  • per i professionisti:
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.


    Richiedi il foglio illustrativo per i professionisti.

Localizzazione

  • Disponibile in:
  • DAPTOMICINA DR REDDY'S
    Italia
  • Lingua:
  • italiano

Informazioni terapeutiche

  • Dettagli prodotto:
  • 044780017 - "350 MG POLVERE PER SOLUZIONE INIETTABILE O PER INFUSIONE" 1 FLACONCINO IN VETRO - autorizzato; 044780029 - "500 MG POLVERE PER SOLUZIONE INIETTABILE O PER INFUSIONE" 1 FLACONCINO IN VETRO - autorizzato

Altre informazioni

Status

  • Fonte:
  • AIFA - Agenzia Italiana del Farmaco
  • Numero dell'autorizzazione:
  • 044780
  • Ultimo aggiornamento:
  • 26-03-2018
  • Il foglio illustrativo per questo prodotto non è al momento disponibile, é possibile inviare una richiesta al nostro Servizio Clienti ed essere avvisati nel momento in cui è disponibile sulla nostra piattaforma.

    Richiedi il foglio illustrativo per il pubblico.

1-9-2018

Multiple “Dr. King’s” homeopathic and “Natural Pet” veterinary products recalled due to potential microbial contamination

Multiple “Dr. King’s” homeopathic and “Natural Pet” veterinary products recalled due to potential microbial contamination

Health Canada is advising consumers and pet owners not to use homeopathic and veterinary products made by King Bio Inc. and labeled as "Dr. King's," "Dr King's Natural Pet" or "Natural Pet." These products may pose a health risk to people and pets, especially children, pregnant women and those with compromised immune systems, because of potential microbial contamination. According to the United States Food and Drug Administration, high levels of microbial contamination were identified at the manufacturin...

Health Canada

28-8-2018

FDA alerts consumers, pet owners not to use products manufactured by King Bio, including Dr. King’s label, homeopathic drug and pet products

FDA alerts consumers, pet owners not to use products manufactured by King Bio, including Dr. King’s label, homeopathic drug and pet products

FDA alerts consumers, pet owners not to use products manufactured by King Bio, including Dr. King’s label, homeopathic drug and pet products

FDA - U.S. Food and Drug Administration

14-9-2018

#FDA's Dr. Binita Ashar provides a statement on continuing the agency’s commitment to studying breast implant safety. To read the statement, click the link:  https://go.usa.gov/xPg4C  #MedicalDevices

#FDA's Dr. Binita Ashar provides a statement on continuing the agency’s commitment to studying breast implant safety. To read the statement, click the link: https://go.usa.gov/xPg4C  #MedicalDevices

#FDA's Dr. Binita Ashar provides a statement on continuing the agency’s commitment to studying breast implant safety. To read the statement, click the link: https://go.usa.gov/xPg4C  #MedicalDevices

FDA - U.S. Food and Drug Administration

13-8-2018

More highlights from today's Pediatric Medical Device Development Public Meeting: Dr. Michelle Tarver of CDRH highlighting that collaboration is imperative in helping to promote pediatric device development. #devices4kids #MedicalDevicepic.twitter.com/mzl

More highlights from today's Pediatric Medical Device Development Public Meeting: Dr. Michelle Tarver of CDRH highlighting that collaboration is imperative in helping to promote pediatric device development. #devices4kids #MedicalDevicepic.twitter.com/mzl

More highlights from today's Pediatric Medical Device Development Public Meeting: Dr. Michelle Tarver of CDRH highlighting that collaboration is imperative in helping to promote pediatric device development. #devices4kids #MedicalDevice pic.twitter.com/mzlmU6Nq9U

FDA - U.S. Food and Drug Administration

2-8-2018

EU/3/18/2043 (Dr Ulrich Granzer)

EU/3/18/2043 (Dr Ulrich Granzer)

EU/3/18/2043 (Active substance: Combination of carboplatin and sodium valproate) - Orphan designation - Commission Decision (2018)5275 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/036/18

Europe -DG Health and Food Safety

29-6-2018

EU/3/18/2037 (Dr Stefan Blesse)

EU/3/18/2037 (Dr Stefan Blesse)

EU/3/18/2037 (Active substance: Omaveloxolone) - Orphan designation - Commission Decision (2018)4182 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/033/18

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2023 (Dr Regenold GmbH)

EU/3/18/2023 (Dr Regenold GmbH)

EU/3/18/2023 (Active substance: H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-225-actinium) - Orphan designation - Commission Decision (2018)3391 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/252/17

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2019 (Dr Stefan Blesse)

EU/3/18/2019 (Dr Stefan Blesse)

EU/3/18/2019 (Active substance: Bardoxolone methyl) - Orphan designation - Commission Decision (2018)3386 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/011/18

Europe -DG Health and Food Safety

18-4-2018

EU/3/18/2007 (Dr Philippe Moullier)

EU/3/18/2007 (Dr Philippe Moullier)

EU/3/18/2007 (Active substance: Adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene) - Orphan designation - Commission Decision (2018)2403 of Wed, 18 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/255/17

Europe -DG Health and Food Safety